A promising approach of overcoming the intrinsic resistance of Candida krusei to fluconazole (FLC) - combining tacrolimus with FLC

FEMS Yeast Research

Volumn 14, Issue 5, 2014, Pages 808-811

  Li, Hui ^a   Zhang, Caiqing ^b   Chen, Zuozhong ^c   Shi, Wenna ^d   Sun, Shujuan ^b  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c ZIBO CENTRAL HOSPITAL   (China)

^d SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Antifungal resistance; Drug combination; Synergy

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; TACROLIMUS;

ANTIFUNGAL RESISTANCE; CANDIDA; DRUG EFFECTS; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST; TIME;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; TACROLIMUS; TIME FACTORS;

EID: 84905566853     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/1567-1364.12163     Document Type: Article

References (14)

1. CLSI (2008) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Third Edition. CLSI Document M27-A3, Wayne, PA.
2. Conen A, Weisser M, Jorg CO et al. (2008) Candida krusei-a serious complication in patients with hematological malignancies: successful treatment with caspofungin. Transpl Infect Dis 10: 66-70.
3. Cruz MC, Goldstein AL, Blankenship JR et al. (2002) Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 21: 546-559.
4. Guinea J (2014) Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect Suppl 6: 5-10.
5. Lamping E, Monk BC, Niimi K et al. (2007) Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell 6: 1150-1165.
6. Lamping E, Ranchod A, Nakamura K et al. (2009) Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob Agents Chemother 53: 354-369.
7. Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1.
8. Panizo MM, Reviakina V, Dolande M & Selgrad S (2009) Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol 47: 137-143.
9. Pelletier R, Alarie I, Lagace R & Walsh TJ (2005) Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 43: 559-564.
10. Pfaller MA, Diekema DJ, Gibbs DL et al. (2008) Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46: 515-521.
11. Sahuquillo-Arce JM, Colombo-Gainza E, Gil-Brusola A, Ortiz-Estevez R, Canton E & Gobernado M (2006) In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter 19: 252-257.
12. Samaranayake YH & Samaranayake LP (1994) Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol 41: 295-310.
13. Sipsas NV & Kontoyiannis DP (2012) Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents 39: 464-471.
14. Sun S, Li Y, Guo Q, Shi C, Yu J & Ma L (2008) In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother 52: 409-417.